Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05923-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Carlos Jiménez-Vicente und 15 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Hospital Clínic de Barcelona, Villarroel 170, 08036, Barcelona, Spain. Hauptthemen laut MEDLINE: Sulfonamides, Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitat de Barcelona.
Abstract (Originalsprache)
Although there is an approved indication for venetoclax and hypomethylating agents (VenHMA) and its use in different AML settings will be expanded in the following years, the management of the adverse events (AEs) lacks of harmonized algorithms during treatment of these patients. We have studied the incidence of relevant AEs of 43 patients who achieved a response to VenHMA and its management. Median overall survival of our cohort was 19 months. No patients discontinued treatment due to AEs after C3D1, Regarding severe AEs, high rates of grade 4 neutropenia (97.6%) and grade 4 thrombocytopenia (65.1%) were observed. Severe infectious AEs rate was 16%. Due to severe myelotoxicity, most patients required a progressive dose reduction of both venetoclax and hypomethylating agents during follow-up, being 87.8% at C6D1. Transfusional dependence rate was 91% and G-CSF was prescribed to 86% of the patients. Finally, there was not a significant difference in hemoglobin, platelets and absolute neutrophil count after achieving complete response comparing paired samples during follow-up, although cytopenia rate was high during initial follow-up. We conclude that dose reduction of VenHMA after achieving a response in patients diagnosed with AML is required in most patients and essential to avoid prolonged cytopenia-related adverse events and a rapid and standardized method on how to perform it might decrease the AEs rate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Department, Hospital Clínic de Barcelona, Villarroel 170, 08036, Barcelona, Spain.
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
- University of Barcelona, Barcelona, Spain.
- Pathology Department. Hospital Clinic, Hemopathology Unit, Barcelona, Spain.
- Hematology Department, Hospital Clínic de Barcelona, Villarroel 170, 08036, Barcelona, Spain. jesteve@clinic.cat.
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. jesteve@clinic.cat.
Förderung
- Universitat de Barcelona
Zitieren
APA
Jiménez-Vicente, C., Guardia-Torrelles, A., Pérez-Valencia, A. I., Martínez-Roca, A., Castaño-Diez, S., Guijarro, F., Cortés-Bullich, A., Merchán, B., Triguero, A., Hernández, I., Brillembourg, H., Munárriz, D., Zugasti, I., Fernández-Avilés, F., Diaz-Beyá, M., & Esteve, J. (2024). Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05923-5
Vancouver
Jiménez-Vicente C, Guardia-Torrelles A, Pérez-Valencia AI, Martínez-Roca A, Castaño-Diez S, Guijarro F, et al. Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05923-5
BibTeX
@article{JimnezVicente2024,
author = {Jiménez-Vicente, Carlos and Guardia-Torrelles, Ares and Pérez-Valencia, Amanda Isabel and Martínez-Roca, Alexandra and Castaño-Diez, Sandra and Guijarro, Francesca and Cortés-Bullich, Albert and Merchán, Beatriz and Triguero, Ana and Hernández, Isabel and Brillembourg, Helena and Munárriz, Daniel and Zugasti, Inés and Fernández-Avilés, Francesc and Diaz-Beyá, Marina and Esteve, Jordi},
title = {Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05923-5}
}
EUVIMED